For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,767,088 | 1,124,727 | 851,537* | 939,067 |
| General and administrative | 1,529,906 | 1,216,656 | 1,340,119* | 964,676 |
| Loss from operations | -4,296,994 | -2,341,383 | -2,191,656* | -1,903,743 |
| Misc other income | - | - | 0* | 0 |
| Reimbursement grant income | 66,228 | 102,425 | 234,051* | 183,281 |
| Interest income | 639 | 47 | 842* | 572 |
| Foreign exchange gain | 12,595 | -8,758 | 29,113* | -29,574 |
| Nonoperating income (expense) | 79,462 | 93,714 | 264,006* | 154,279 |
| Loss before income taxes | -4,217,532 | - | -1,927,650* | -1,749,464 |
| Income tax expense | 800 | - | 800* | 0 |
| Net loss | -4,218,332 | -2,247,669 | -1,928,450* | -1,749,464 |
| Exchange differences on translation | -15,003 | -5,315 | -416,991* | 164,611 |
| Net comprehensive loss | -4,233,335 | -2,252,984 | -2,345,441 | -1,584,853 |
| Basic EPS | -0.49 | -0.28 | -0.542 | -0.25 |
| Basic Average Shares | 8,541,146 | 7,972,532 | 4,330,738 | 7,022,678 |
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)